e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Old and new topics in environmental and occupational lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Talc-associated lung damage by chronic injection drug use on evidence of forensic autopsies
L. Grinberg, A. Nevolin, D. Kondrashov (Yekaterinburg, Russian Federation)
Source:
Annual Congress 2009 - Old and new topics in environmental and occupational lung disease
Session:
Old and new topics in environmental and occupational lung disease
Session type:
E-Communication Session
Number:
3179
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Grinberg, A. Nevolin, D. Kondrashov (Yekaterinburg, Russian Federation). Talc-associated lung damage by chronic injection drug use on evidence of forensic autopsies. Eur Respir J 2009; 34: Suppl. 53, 3179
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Lung function in epidemiological studies from infancy to childhood with focus on urban environment
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Related content which might interest you:
The use of a murine model of brain death for mechanistic studies on treatment for donor lung injury
Source: Annual Congress 2011 - Improving outcomes after lung transplantation
Year: 2011
The histopathalogical evaluation of administration route of bleomycin in pulmonary fibrosis model and contribution of smoking to development of fibrosis
Source: Annual Congress 2007 - Pathogenesis of idiopathic interstitial pneumonia including idiopathic pulmonary fibrosis
Year: 2007
Utility of drug reaction assessments for inhaled therapies in patients with chronic suppurative lung diseases: results from 5 years of drug reaction assessments
Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Year: 2018
Development of inhalation therapy for prevention and treatment of acute lung injury
Source: Annual Congress 2010 - Acute respiratory failure
Year: 2010
Role of lung biopsies in the diagnosis of interstitial lung diseases in a clinical real-life setting
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021
The use of bronchospheres to study chronic lung diseases
Source: International Congress 2018 – Organoids and pluripotent stem cells
Year: 2018
A novel approach for optimal lung recruitment in acute lung injury
Source: Annual Congress 2005 - Pulmonary function outcome, respiratory morbidity in prematurely born children and acute lung injury
Year: 2005
Sputum induction for assessment of biomarkers in early development of new drugs for respiratory disease in a proof of concept setting
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Drug-induced infiltrative lung disease
Source: Eur Respir J 2001; 18: 93S-100S
Year: 2001
Does surgical lung biopsy change the diagnosis and treatment in interstitial lung diseases?
Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease
Year: 2010
Frequency, severity and risk factors of drug-induced liver injury during treatment of new tuberculosis patients
Source: Annual Congress 2012 - Tuberculosis: clinical findings III
Year: 2012
Indications and patterns of use of benzodiazepines and opioids in severe interstitial lung disease: a population-based longitudinal study
Source: ERJ Open Res, 7 (1) 00716-2020; 10.1183/23120541.00716-2020
Year: 2021
Paracetamol use and asthma: an overview of evidence implicating adult exposure
Source: Annual Congress 2012 - Paracetamol and asthma: a causal link?
Year: 2012
Clinical management implications of histologic information provided by lung biopsy in the multidisciplinary evaluation of interstitial lung diseases.
Source: Virtual Congress 2020 – The hot and cold of interventional pulmonology
Year: 2020
Systemic biomarkers in electronic cigarette users: implications for noninvasive assessment of vaping-associated pulmonary injuries
Source: ERJ Open Res, 5 (4) 00182-2019; 10.1183/23120541.00182-2019
Year: 2019
Combined application of surfactant-BL administration and lung recruitment maneuver for treatment of ARDS of different genesis
Source: Annual Congress 2009 - Acute lung injury and biomarkers
Year: 2009
Prediction of chronic lung allograft dysfunction: a systems medicine challenge
Source: Eur Respir J 2014; 43: 689-693
Year: 2014
Acute lung injury as a possible adverse drug reaction related to gefitinib
Source: Eur Respir J 2002 Jan 01;22(1):179-181
Year: 2003
Use of expression microarrays in studies of asthma, acute lung injury and emphysema
Source: Lung Science Conference 2004 - Application of our knowledge of the basic processes of lung inflammation in lung diseases
Year: 2004
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept